XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.19.2

Equity | 6 Months Ended
--- | ---
Jun. 30, 2019
Equity [Abstract] |
Equity | Equity
| Three Months Ended June 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- Controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at April 1, 2018 | 3,577 |  | $ | 1,788 |  | $ | 39,874 |  | $ | 41,107 |  | $ | (5,060 | ) | 885 |  | $ | (44,041 | ) | $ | 233 |  | $ | 33,901 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 1,707 |  | — |  | — |  | — |  | — |  | 1,707 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (62 | ) | — |  | — |  | — |  | (62 | )
Cash dividends declared on common stock ($0.48 per share) | — |  | — |  | — |  | (1,291 | ) | — |  | — |  | — |  | — |  | (1,291 | )
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 27 |  | (1,596 | ) | — |  | (1,596 | )
Share-based compensation plans and other | — |  | — |  | (133 | ) | — |  | — |  | (5 | ) | 236 |  | — |  | 103 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 9 |  | 9 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (5 | ) | (5 | )
Balance at June 30, 2018 | 3,577 |  | $ | 1,788 |  | $ | 39,741 |  | $ | 41,523 |  | $ | (5,122 | ) | 907 |  | $ | (45,401 | ) | $ | 237 |  | $ | 32,766 |
Balance at April 1, 2019 | 3,577 |  | $ | 1,788 |  | $ | 38,768 |  | $ | 44,065 |  | $ | (5,346 | ) | 994 |  | $ | (51,736 | ) | $ | 131 |  | $ | 27,670 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 2,670 |  | — |  | — |  | — |  | — |  | 2,670 |
Other comprehensive loss, net of taxes | — |  | — |  | — |  | — |  | (16 | ) | — |  | — |  | — |  | (16 | )
Cash dividends declared on common stock ($0.55 per share) | — |  | — |  | — |  | (1,440 | ) | — |  | — |  | — |  | — |  | (1,440 | )
Treasury stock shares purchased | — |  | — |  | 1,000 |  | — |  | — |  | 24 |  | (2,235 | ) | — |  | (1,235 | )
Share-based compensation plans and other | — |  | — |  | (284 | ) | — |  | — |  | (8 | ) | 401 |  | — |  | 117 |
Net loss attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (26 | ) | (26 | )
Other changes in noncontrolling ownership interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (3 | ) | (3 | )
Balance at June 30, 2019 | 3,577 |  | $ | 1,788 |  | $ | 39,484 |  | $ | 45,295 |  | $ | (5,362 | ) | 1,010 |  | $ | (53,570 | ) | $ | 102 |  | $ | 27,737 |
| Six Months Ended June 30,
| Common Stock | Other Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Treasury Stock | Non- Controlling Interests | Total
($ and shares in millions except per share amounts) | Shares | Par Value | Shares | Cost
Balance at January 1, 2018 | 3,577 |  | $ | 1,788 |  | $ | 39,902 |  | $ | 41,350 |  | $ | (4,910 | ) | 880 |  | $ | (43,794 | ) | $ | 233 |  | $ | 34,569 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 2,443 |  | — |  | — |  | — |  | — |  | 2,443 |
Adoption of new accounting standards | — |  | — |  | — |  | 322 |  | (274 | ) | — |  | — |  | — |  | 48 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 62 |  | — |  | — |  | — |  | 62 |
Cash dividends declared on common stock ($0.96 per share) | — |  | — |  | — |  | (2,592 | ) | — |  | — |  | — |  | — |  | (2,592 | )
Treasury stock shares purchased | — |  | — |  | — |  | — |  | — |  | 37 |  | (2,162 | ) | — |  | (2,162 | )
Share-based compensation plans and other | — |  | — |  | (161 | ) | — |  | — |  | (10 | ) | 555 |  | — |  | 394 |
Net income attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | 14 |  | 14 |
Distributions attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (10 | ) | (10 | )
Balance at June 30, 2018 | 3,577 |  | $ | 1,788 |  | $ | 39,741 |  | $ | 41,523 |  | $ | (5,122 | ) | 907 |  | $ | (45,401 | ) | $ | 237 |  | $ | 32,766 |
Balance at January 1, 2019 | 3,577 |  | $ | 1,788 |  | $ | 38,808 |  | $ | 42,579 |  | $ | (5,545 | ) | 985 |  | $ | (50,929 | ) | $ | 181 |  | $ | 26,882 |
Net income attributable to Merck & Co., Inc. | — |  | — |  | — |  | 5,585 |  | — |  | — |  | — |  | — |  | 5,585 |
Other comprehensive income, net of taxes | — |  | — |  | — |  | — |  | 183 |  | — |  | — |  | — |  | 183 |
Cash dividends declared on common stock ($1.10 per share) | — |  | — |  | — |  | (2,869 | ) | — |  | — |  | — |  | — |  | (2,869 | )
Treasury stock shares purchased | — |  | — |  | 1,000 |  | — |  | — |  | 38 |  | (3,325 | ) | — |  | (2,325 | )
Share-based compensation plans and other | — |  | — |  | (324 | ) | — |  | — |  | (13 | ) | 684 |  | — |  | 360 |
Net loss attributable to noncontrolling interests | — |  | — |  | — |  | — |  | — |  | — |  | — |  | (79 | ) | (79 | )
Balance at June 30, 2019 | 3,577 |  | $ | 1,788 |  | $ | 39,484 |  | $ | 45,295 |  | $ | (5,362 | ) | 1,010 |  | $ | (53,570 | ) | $ | 102 |  | $ | 27,737 |
On October 25, 2018, the Company entered into accelerated share repurchase (ASR) agreements with two third-party financial institutions (Dealers). Under the ASR agreements, Merck agreed to purchase $5 billion of Merck’s common stock, in total, with an initial delivery of 56.7 million shares of Merck’s common stock, based on the then-current market price, made by the Dealers to Merck, and payments of $5 billion made by Merck to the Dealers on October 29, 2018, which were funded with existing cash and investments, as well as short-term borrowings. The payments to the Dealers were recorded as reductions to shareholders’ equity, consisting of a $4 billion increase in treasury stock, which reflected the value of the initial 56.7 million shares received on October 29, 2018, and a $1 billion decrease in other-paid-in capital, which reflected the value of the stock held back by the Dealers pending final settlement. Upon settlement of the ASR agreements in April 2019, Merck received an additional 7.7 million shares as determined by the average daily volume weighted-average price of Merck’s common stock during the term of the ASR program, less a negotiated discount, bringing the total shares received by Merck under this program to 64.4 million. The receipt of the additional shares was reflected as an increase to treasury stock and an increase to other-paid-in capital in the second quarter of 2019.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -URI http://asc.fasb.org/topic&trid=2208762 + Details
Name: | us-gaap_StockholdersEquityNoteDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration